Editas Medicine Inc (NAS:EDIT)
$ 5.3 -0.13 (-2.39%) Market Cap: 435.86 Mil Enterprise Value: 184.52 Mil PE Ratio: 0 PB Ratio: 1.48 GF Score: 52/100

Editas Medicine Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 06:15PM GMT
Release Date Price: $24.28 (-0.74%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

(technical difficulty)

With the next session. Thanks for joining us this afternoon. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Before we start, I just need to read the disclosure statement.

Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures, or you can pick up a copy at the registration desk.

So I'm very happy to have the team from Editas with me here. Cindy, I don't know if you want to make any opening comments. If not, we can jump right in. But...

Cynthia L. Collins
Editas Medicine, Inc. - CEO, President & Director

Yes. We can jump right in. That'd be great.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Okay. Great. Great. So look, I thought maybe a good place

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot